20240026028. ANTI-HER3 ANTIBODY AND ANTI-HER3 ANTIBODY-DRUG CONJUGATE AND MEDICAL USE THEREOF simplified abstract (JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.)
ANTI-HER3 ANTIBODY AND ANTI-HER3 ANTIBODY-DRUG CONJUGATE AND MEDICAL USE THEREOF
Organization Name
JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
Inventor(s)
ANTI-HER3 ANTIBODY AND ANTI-HER3 ANTIBODY-DRUG CONJUGATE AND MEDICAL USE THEREOF - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240026028 titled 'ANTI-HER3 ANTIBODY AND ANTI-HER3 ANTIBODY-DRUG CONJUGATE AND MEDICAL USE THEREOF
Simplified Explanation
The abstract of the patent application describes an anti-HER3 antibody and an anti-HER3 antibody-drug conjugate, along with their medical use. The anti-HER3 antibody is represented by the general formula (pc-l-y-d), where pc is the anti-HER3 antibody, and l, y, and n are defined in the description.
- The patent application describes an anti-HER3 antibody and an antibody-drug conjugate.
- The anti-HER3 antibody is represented by the formula (pc-l-y-d), with pc being the antibody.
- The invention has a medical use, although the specific details are not provided in the abstract.
- The abstract mentions that the values of l, y, and n are defined in the description.
Potential Applications:
- Targeted therapy for HER3-positive cancers: The anti-HER3 antibody and antibody-drug conjugate can be used to specifically target and treat cancers that overexpress HER3.
- Combination therapy: The anti-HER3 antibody-drug conjugate can be used in combination with other therapies to enhance their efficacy in treating HER3-positive cancers.
Problems Solved:
- Limited treatment options for HER3-positive cancers: The invention provides a new therapeutic approach for HER3-positive cancers, addressing the limited treatment options currently available.
- Non-specific drug delivery: The antibody-drug conjugate allows for targeted drug delivery to HER3-expressing cancer cells, reducing off-target effects and improving treatment outcomes.
Benefits:
- Enhanced efficacy: The targeted delivery of drugs to HER3-expressing cancer cells improves the efficacy of treatment, potentially leading to better patient outcomes.
- Reduced side effects: By specifically targeting HER3-expressing cells, the antibody-drug conjugate minimizes damage to healthy cells, reducing the occurrence of side effects associated with non-specific drug delivery.
Original Abstract Submitted
provided are an anti-her3 antibody and an anti-her3 antibody-drug conjugate and a medical use thereof, specifically, the anti-her3 antibody, and the anti-her3 antibody-drug conjugate as represented by general formula (pc-l-y-d), wherein pc is an anti-her3 antibody, and l, y and n are as defined in the description.
